Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Advice programme

Showing 1 to 25 of 39

TitleReference numberPublishedLast updated
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TA982
Bimekizumab for treating active psoriatic arthritisTA916
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDsTA815
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA803
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA768
Upadacitinib for treating moderate rheumatoid arthritisTA744
Tofacitinib for treating juvenile idiopathic arthritisTA735
Lateral elbow resurfacing for arthritisHTG591
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failedTA715
Filgotinib for treating moderate to severe rheumatoid arthritisTA676
Upadacitinib for treating severe rheumatoid arthritisTA665
Rheumatoid arthritis in adults: managementNG100
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritisES29
Rheumatoid arthritis in over 16sQS33
Midcarpal hemiarthroplasty for wrist arthritisHTG529
Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritisHTG521
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)TA568
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA543
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA537
Total distal radioulnar joint replacement for symptomatic joint instability or arthritisHTG451
Sarilumab for moderate to severe rheumatoid arthritisTA485
Tofacitinib for moderate to severe rheumatoid arthritisTA480
Baricitinib for moderate to severe rheumatoid arthritisTA466
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDsTA445

Results per page

  1. 10
  2. 25
  3. 50
  4. All